Crescent Biopharma, Inc. insider trading
Every open-market purchase and sale by Crescent Biopharma, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Crescent Biopharma, Inc.’s insiders pay?
From June 13, 2014 to July 20, 2026, 21 insiders reported 26 open-market purchases and 15 sales not made under a pre-set plan in Crescent Biopharma, Inc. Twelve months after each purchase was reported, the shares were +71.8% against the S&P 500 on average (median +71.8%), over 2 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −31.1% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 16, 2014 into $31,672 by November 2, 2026, +9.8% a year. It held shares 26% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,846 (+6.1% a year), and held throughout $47,966 (+13.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Junius Daniel M | Director | 5 | +160.7% (1) | 100% | 0 | — | May 11, 2023 |
| Rock Edwin | Chief Medical Officer | 4 | — | — | 0 | — | June 24, 2024 |
| Henos Michael A | Director | 1 | — | — | 2 | — | December 23, 2014 |
| Sandell Scott D | 10% owner | 0 | — | — | 3 | — | January 27, 2023 |
| Siren, L.L.C. | 10% owner | 0 | — | — | 3 | — | August 9, 2024 |
| Thackray Helen M. | SVP Clinical Development, CMO | 0 | — | — | 3 | −9.7% (3) | December 12, 2017 |
| Wittouck Amaury | 10% owner | 3 | — | — | 0 | — | February 28, 2023 |
| Bvf Inc/il | 10% owner | 2 | — | — | 0 | — | November 6, 2020 |
| Hahn Brian M. | SVP Finance, CFO | 1 | — | — | 1 | −42.1% (1) | November 14, 2022 |
| Magnani John L. | SVP of Research, CSO | 1 | — | — | 1 | −74.1% (1) | November 14, 2022 |
| Andrews Patricia S | Director | 1 | — | — | 0 | — | November 18, 2021 |
| Artal Group S.A. | 10% owner | 1 | — | — | 0 | — | February 23, 2023 |
| Barrett M James | Director | 0 | — | — | 1 | −41.1% (1) | May 11, 2018 |
| Biotechnology Value Fund II LP | 10% owner | 1 | — | — | 0 | — | September 9, 2019 |
| Fairmount Healthcare Fund II L.P. | Director | 1 | — | — | 0 | — | July 20, 2026 |
| Goldberg Mark Alan | Director | 1 | −17.1% (1) | 0% | 0 | — | March 7, 2016 |
| Harwin Peter Evan | Director | 1 | — | — | 0 | — | December 8, 2025 |
| Invus Public Equities Advisors, LLC | 10% owner | 0 | — | — | 1 | — | August 7, 2024 |
| Johnson Bruce S | SVP & Chief Commercial Officer | 1 | — | — | 0 | — | May 9, 2023 |
| Pearson Timothy R | Director | 1 | — | — | 0 | — | November 14, 2022 |
| Semerjian Harout | Chief Executive Officer | 1 | — | — | 0 | — | November 14, 2022 |
When several insiders traded Crescent Biopharma, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Crescent Biopharma, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 1 selling crowd, −34.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 29, 2018 | 3 selling | −18.4% | −34.4% | −39.1% |